Brainomix, a British stroke imaging software firm, has partnered with Medtronic’s Neurovascular business unit to improve stroke care in Western Europe.
By integrating advanced artificial intelligence (AI) solutions, the partnership aims to enhance clinical practice, increase access to treatments, and improve patient outcomes.
The collaboration will combine the Brainomix 360 Stroke platform with Medtronic’s expertise in neurovascular treatments to advance stroke care.
It will enable faster, more accurate diagnoses, helping healthcare professionals make better-informed decisions and deliver life-saving treatments more efficiently.
The Brainomix 360 Stroke platform uses advanced AI algorithms for real-time brain scan interpretation, helping with treatment and transfer decisions for stroke patients.
It received US Food and Drug Administration (FDA) clearance in March 2023.
According to Brainomix, its flagship AI platform showed a doubling of thrombectomy rates at Brainomix sites in a real-world stroke AI study that involved over 450,000 patients in England over five years. These sites also saw a 37% higher rate compared to non-evaluation sites.
Brainomix CEO and co-founder Michalis Papadakis said: “This partnership with Medtronic is a natural fit, with the leading neurovascular device provider joining forces with the leading stroke AI imaging partner, both aligned around a mutual commitment towards improving stroke care for all patients.”
Brainomix said that the key benefits of the partnership include transforming treatment regionally.
Medtronic’s presence in Western Europe will accelerate the adoption of Brainomix’s AI technology. This will ensure that life-saving innovations reach more hospitals and healthcare providers across the region.
The integration will also enhance diagnostic accuracy, providing healthcare professionals with precise tools for quicker, more informed decisions, which are crucial for timely stroke treatment.
Additionally, the partnership with Medtronic will optimise clinical workflows by simplifying and speeding up stroke detection and intervention, the imaging company said. This will help alleviate the burden on healthcare providers and boost efficiency across hospital networks.
Brainomix specialises in developing AI-powered software solutions that enable precision medicine, improving treatment decisions in stroke and lung fibrosis.
Originally a spin-out from the University of Oxford, Brainomix is now a commercial-stage company with offices in the UK, Ireland, and the US, and operations in over 30 countries.
In July last year, the imaging firm collaborated with the German pharmaceutical company Boehringer Ingelheim to improve the care of patients with fibrosing lung disease in the US.
